

AREA PRESCRIBING COMMITTEE – Birmingham, Sandwell, Solihull and environs

Decision Making Support Tool

The following document supports the committee to consider formulary applications against defined criteria.

Formulary application reference:	APCBSSE/0080	
Drug name and formulations:	Trimbow® (beclometasone dipropionate, formoterol fumarate dihydrate, glycopyrronium bromide)	
Criteria	Example	Committee Consensus
Patient Safety	<i>Potential for abuse, toxicity, significant drug interactions</i>	Adverse effects comparable to inhalers containing constituent ingredients. Pneumonia reported in small number of patients.
Clinical effectiveness	<i>Established licensed product</i>	Evidence of reduction in COPD exacerbations, demonstrating superiority to inhalers containing constituent ingredients
Strength of evidence		Robust
Cost effectiveness or resource impact	£	Cost effective compared to using two separate inhalers containing constituent ingredients
Place of therapy relative to available treatments	<i>1/2nd tier</i>	In line with COPD guidance
National guidance and priorities	<i>NICE, MTRAC</i>	Not reviewed by MTRAC
Local health priorities	<i>CCG views</i>	CCGs supportive
Equity of access	<i>Equality assessment</i>	N/A
Stakeholder views	<i>Define wider groups to be engaged</i>	N/A
Implementation requirements	<i>Requires, RICAD ESCA etc.</i>	In line with COPD guidance

Decision Summary

Resubmission is recommended to complete the information to enable a decision:	
Not approved and rationale:	
Formulary status (RAG) and rationale	GREEN
Implementation requirements:	
Implementation monitoring:	